Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,382 across all filing types
Latest filing 2013-11-07 Share Issue/Capital Cha…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document title is "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of a specific date (October 31, 2013). This content directly relates to the structure of the company's capital and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it is a mandatory periodic disclosure regarding the capital base, even though it is not a change announcement, but a status report on capital structure. It is not a general regulatory filing (RNS) because it fits a specific category related to capital structure.
2013-11-07 French
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and references Article 223-16 of the AMF General Regulations. It provides a table showing the total number of shares and total voting rights as of a specific date (October 31, 2013). This type of periodic disclosure regarding share capital and voting rights does not fit neatly into the primary categories like 10-K, ER, or IR. It is a specific regulatory disclosure concerning share structure. Since there is no specific code for 'Voting Rights Disclosure' other than DVA (Declaration of Voting Results), and this is a monthly update on the *total* rights rather than the *results* of a vote, the most appropriate fallback category is Regulatory Filings (RNS), as it is a mandatory, periodic regulatory disclosure that doesn't match the other specific definitions.
2013-11-07 English
Share buybacks / Liquidity contracts Description of share buyback program
Transaction in Own Shares Classification · 98% confidence The document is a press release dated November 6, 2013, announcing that Ipsen has initiated a share buy-back program to cover restricted share plans. The core subject is the company purchasing its own shares (0.95% of capital) over a specified period. This action directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance). Therefore, the appropriate filing type code is POS.
2013-11-06 English
Rachat d'actions / Contrat de liquidité Descriptif du programme de rachat
Transaction in Own Shares Classification · 98% confidence The document text explicitly announces a share repurchase program ('programme de rachat d'actions') by Ipsen, stating the number of shares to be bought back (800,000) and the duration of the mandate. This action falls directly under the definition of a company buying back or selling its own shares. This corresponds to the 'Transaction in Own Shares' category.
2013-11-06 French
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Interim / Quarterly Report Classification · 95% confidence The document is a detailed report of Ipsen's sales performance for the third quarter and first nine months of 2013. It includes specific financial tables, breakdowns by region and therapeutic area, and management commentary on financial results. It is not a mere announcement of a report (RPA) nor a simple earnings release (ER) as it provides comprehensive analysis and data tables. It fits the definition of an Interim/Quarterly Report (IR) as it covers a period shorter than a full fiscal year and contains substantive financial data. 9M 2013
2013-10-30 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 98% confidence The document is titled "Ipsen: chiffre d'affaires du 3ème trimestre et des neuf premiers mois de 2013" (Ipsen: Revenue for the 3rd quarter and the first nine months of 2013). It contains detailed financial tables showing revenue figures for the 3rd quarter and year-to-date (neuf premiers mois) of 2013 compared to 2012, segmented by geography and therapeutic area. It also includes commentary from the CEO on performance and confirmation of 2013 financial objectives. This content structure—reporting specific periodic financial results (quarterly and nine-month) with detailed breakdowns and management commentary—is characteristic of an Interim/Quarterly Report (IR). It is too detailed to be a simple Earnings Release (ER) and is not the full annual filing (10-K). 9M 2013
2013-10-30 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.